MITF Regulates CFTR Expression to Participate in Myocardial Ischemia-Reperfusion Injury

Baoxin Tang1, Chenying Zhu2, Heqing Wang3

  • 1Department of Cardiology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.

Abstract

Insights

Microphthalmia-associated transcription factor (MITF) regulates cystic fibrosis transmembrane conductance regulator (CFTR) expression in myocardial ischemia-reperfusion injury (MIRI). Disruption of the MITF-CFTR axis worsens MIRI, but restoring CFTR can mitigate damage.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Gene Regulation

Background:

  • Myocardial ischemia-reperfusion injury (MIRI) is a significant clinical challenge with incompletely understood regulatory mechanisms.
  • Identifying key molecular targets is crucial for understanding and potentially treating MIRI.

Purpose of the Study:

  • To identify key genes involved in MIRI.
  • To elucidate the regulatory role of microphthalmia-associated transcription factor (MITF) and cystic fibrosis transmembrane conductance regulator (CFTR) in MIRI.

Main Methods:

  • Bioinformatic analysis of GEO datasets (GSE6381, GSE249812, GSE123342) to identify core MIRI genes.
  • In vitro studies using oxygen-glucose deprivation/reoxygenation (OGD/OGR) models in AC16 cells to assess MITF and CFTR manipulation effects.
  • In vivo studies using a rat ischemia-reperfusion (I/R) model to evaluate the impact of MITF and CFTR modulation on cardiac injury.

Main Results:

  • 42 core MIRI-related genes were identified, with CFTR consistently upregulated.
  • MITF was identified as a key transcription factor regulating CFTR expression in MIRI models.
  • MITF or CFTR knockdown exacerbated cellular damage and apoptosis, while overexpression or CFTR rescue showed protective effects in vitro and in vivo.

Conclusions:

  • The MITF-CFTR axis plays a critical role in regulating MIRI.
  • Disruption of this axis leads to aggravated cardiac injury.
  • Targeting the MITF-CFTR pathway offers a potential therapeutic strategy for MIRI.